CStone Pharmaceuticals Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

CStone Pharmaceuticals şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.01%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.01%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PH4 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PH4 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

CStone Pharmaceuticals Piyasaya Karşı Temettü Getirisi

PH4 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PH4)	n/a
Pazarın Alt %25'i (DE)	1.7%
Pazarın En İyi %25'i (DE)	4.9%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (PH4) (3 yıla kadar)	0%

Önemli Temettü: PH4 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PH4 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PH4 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PH4 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

CStone Pharmaceuticals Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Non-Executive Director recently bought €223k worth of stock

CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

Key Executive recently bought €181k worth of stock

New minor risk - Profitability

CStone Pharmaceuticals to Report First Half, 2024 Results on Aug 23, 2024

CStone Pharmaceuticals Announces European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer

CStone Pharmaceuticals Announces Change of Joint Company Secretary

CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024

CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024

CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

Full year 2023 earnings released: CN¥0.29 loss per share (vs CN¥0.77 loss in FY 2022)

New minor risk - Financial data availability

CStone Announces the Availability of RET Inhibitor GAVRETO® (palsetinib) Manufacturing Localization Application by Center for Drug Evalence of China NMPA

Forecast to breakeven in 2026

CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

Less than half of directors are independent

Less than half of directors are independent

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma

New major risk - Share price stability

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma

CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma

New major risk - Share price stability

First half 2023 earnings released: CN¥0.17 loss per share (vs CN¥0.31 loss in 1H 2022)

Less than half of directors are independent

CStone Pharmaceuticals Announces Receipt of GCP Inspection Notification from the European Medicines Agency Regarding the Marketing Authorization Application

CEO, Senior VP & Chief Medical Officer recently bought €131k worth of stock

CStone Pharmaceuticals Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023

CEO, Senior VP & Chief Medical Officer recently bought €64k worth of stock

CStone Pharmaceuticals Announces GAVRETO SNDA Approval by China NMPA for First-Line Treatment of Patients with Locally Advanced or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer

CEO, Senior VP & Chief Medical Officer recently bought €53k worth of stock

CStone Pharmaceuticals Announces New Data on AYVAKIT (Avapritinib) in Patients with Advanced Gastrointestinal Stromal Tumor at ASCO 2023

CEO, Senior VP & Chief Medical Officer recently bought €53k worth of stock

Less than half of directors are independent

Full year 2022 earnings released: CN¥0.77 loss per share (vs CN¥1.65 loss in FY 2021)

Forecast to breakeven in 2024

No longer forecast to breakeven

CStone Pharmaceuticals has completed a Follow-on Equity Offering in the amount of HKD 392.8784 million.

CStone Pharmaceuticals Provides Earning Guidance for the Year Ended December 31, 2022

Cstone Pharmaceuticals Announces Management Changes

CStone Pharmaceuticals Announces the NDA Approval of GAVRETO (Pralsetinib) for the Treatment of Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer and Ret-Altered Thyroid Cancer in Taiwan, China

CStone Pharmaceuticals Announces Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints

CStone Pharmaceuticals Announces Results from the Navigator China Bridging Study of AYVAKIT(avapritinib) Published in the Oncologist

Cstone Pharmaceuticals Presents Updated Data for Gavreto (Pralsetinib) in Chinese Patients with Ret-Fusion Positive Non-Small Cell Lung Cancer at Esmo Asia Congress 2022

CEO, Senior VP & Chief Medical Officer recently bought €276k worth of stock

Less than half of directors are independent

Forecast to breakeven in 2024

CEO, Senior VP & Chief Medical Officer recently bought €85k worth of stock

National Medical Products Administration of China Accepts and Grants Priority Review to the Supplemental New Drug Application (sNDA) for sugemalimab of CStone Pharmaceuticals

CStone Pharmaceuticals Announces Acceptance of Priority Review to the Supplemental New Drug Application for Sugemalimab

CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022

CStone Pharmaceuticals Presents Updated Results of Registrational Study of Sugemalimab in Patients with Stage III NSCLC at WCLC 2022

CStone Pharmaceuticals Announces Executive Changes

Hong Kong, China Approve GAVRETO of CStone Pharmaceuticals

CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

Forecast to breakeven in 2024

Less than half of directors are independent

CStone Pharmaceuticals, Annual General Meeting, Jun 30, 2022

CStone Pharmaceuticals Presents Pre-Specified Overall Survival Data of Sugemalimab for First-Line Treatment of Stage Iv Non-Small Cell Lung Cancer At Asco 2022

Less than half of directors are independent

CStone Pharmaceuticals Presents Updated Results of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma at ASCO 2022

CStone Pharmaceuticals Presents Clinical Results of Sugemalimab in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma Via an Oral Abstract Session At ASCO 2022

CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC

CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of Tibsovo

CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific Antibody-Based Therapeutic Candidate CS2006/NM21-1480 At the American Association for Cancer Research (AACR) Annual Meeting 2022

CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Clinical Trial of Cs5001, A Potential Global Best-In-Class Ror1-Targeting ADC

CStone Pharmaceuticals to Report Fiscal Year 2021 Results on Mar 24, 2022

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China

CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibsovo® (Ivosidenib Tablets) as A New Precision Therapy for Patients with Acute Myeloid Leukemia

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

CStone Pharmaceuticals Announces Two Key Phase 3 Registrational Clinical Trials of Sugemalimab Completed Patient Enrollment

Cstone Pharmaceuticals Announces the Registrational Clinical Study Results of Sugemalimab in Stage IV Non-Small Cell Lung Cancer Published in the Lancet Oncology

CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response Rate (ORR) in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

CStone Announces IND Approval for the Pivotal Study in China of Lorlatinib for the Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer

CStone Pharmaceuticals Announces the IND Approval of CS5001, a Potential Global Best-In-Class ROR1-Targeting ADC by the U.S. Food and Drug Administration

CStone Announces New Drug Approval of Precision Therapy AYVAKIT® (Avapritinib) in Hong Kong, China for the Treatment of PDGFRA D842V Mutant Gastrointestinal Stromal Tumors (GIST)